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A B S T R A C T
There is considerable evidence suggesting, that older antiepileptic drugs (AEDs) and some of the newer
ones decrease bone mineral density (BMD). However, there is only limited and conﬂicting data
concerning the effect of levetiracetam on BMD. In this cross-sectional study we analysed data from 168
adult consecutive outpatients treated with AEDs for more than 2 years, and who underwent
measurement of the BMD. We compared the incidence of decreased BMD among the patients treated
with 6 different AEDs: carbamazepine (CBZ), oxcarbazepine (OXC), valproic acid (VPA), lamotrigine
(LTG), topiramate (TPM) and levetiracetam (LEV). Among the patients on monotherapy, reduced BMD
was present signiﬁcantly most often in patients treated with LEV and those treated with OXC. In the
group of patients on polytherapy there was no signiﬁcant difference in the incidence of low BMD among
patients treated with various AEDs. Our data suggest that patients on long-term treatment with LEV have
a higher risk for affection of bone density.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Long term medical therapy with antiepileptic drugs (AEDs) is
detrimental for bone mineralisation.1 There is increasing evidence
suggesting that most of the old AEDs decrease bone mineral
density (BMD) in adults, and there are a few and small studies on
the newer ones (gabapentin, oxcarbazepin, zonisamide) (for a
review see Ref.2). Several studies suggested that treatment with
lamotrigine (LTG) does not affect BMD.3–5 There are only few and
controversial data concerning the effect of levetiracetam (LEV) on
BMD. In rats treatment with LEV decreased signiﬁcantly the bone
biomechanical strength parameters.6 However, BMD seemed
unaffected by the LEV treatment in rats.6 One study on 16 adult
patients treated with LEV did not ﬁnd signiﬁcant decrease in BMD.7
Decreased BMD was found in patients treated with OXC, but both
studies were on children.8,9
The purpose of our study was to investigate the effect of
different AEDs on the bone mineralisation. We compared the
incidence of reduced BMD among adult patients treated with
various AEDs.
2. Methods
In this cross-sectional study we retrospectively analysed data
from 168 adult outpatients with epilepsy treated with various* Corresponding author. Tel.: +45 3863 3029.
E-mail address: noemi@dadlnet.dk (N.B. Andersen).
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BMD. Based on evidence for increased risk of decreased BMD in
patients on long-term treatment with AEDs, according to the local
guidelines we offer BMD measurement to all adult patients who
have been treated with AEDs for more than 2 years. All patients
gave their informed consent in accordance to the declaration of
Helsinki.10 The mean age was 43.3 years (range: 17–77; median:
44 years). The group comprised 65 female (39%) and 103 male
(61%) patients.
The patients were treated with 6 different AEDs: LTG, LEV, CBZ,
OXC, VPA, and TPM. One-hundred-and-eight patients were on
monotherapy, and 60 patients were on two or more AEDs. Mean
duration of treatment was 14 years (range: 2–29; median: 10 years).
BMD was measured in the lumbar spine and the total hip,
including femoral neck and trochanter, using a Lunar DEXA-
scanner (GE Healthcare, Madison, WI). T scores (number of SD
below peak bone mass) were calculated. Low BMD: osteopenia (T
score between 1 and 2.5 SD) and osteoporosis (T score lower
than 2.5 SD) were deﬁned according to WHO criteria.11
The incidence of patients with low BMD among the patients
treated with the 6 different AEDs and the gender distribution was
assessed using chi square test. The age distribution was compared
among the groups using t-test. The level of statistical signiﬁcance
was set to 0.05.
3. Results
Forty-nine patients on monotherapy (45.3%) and 26 patients on
polytherapy (43.3%) had decreased BMD (Table 1).vier Ltd. All rights reserved.
Table 1
Incidence of patients with low bone mineral density (BMD) among the patients
treated with six antiepileptic drugs (AEDs). TPM: topiramate, LTG: lamotrigine,
CBZ: carbamazepine, VPA: valproic acid, OXC: oxacarbazepine, LEV: levetiracetam.
AEDs Monotherapy Polytherapy
Low BMD (%) Total Low BMD (%) Total
TPM 2 (22%) 9 7 (43%) 16
LTG 16 (37%) 43 15 (42%) 35
CBZ 5 (41%) 12 4 (50%) 8
VPA 6 (40%) 15 10 (52%) 19
OXC 8 (67%) 12 3 (33%) 9
LEV 12 (70%) 17 7 (44%) 16
Table 2
Demographic data, duration of treatment and percentage of osteopenia and
osteoporosis for the patients on monotherapy. TPM: topiramate, LTG: lamotrigine,
CBZ: carbamazepine, VPA: valproic acid, OXC: oxacarbazepine, LEV: levetiracetam.
AEDs Age
Mean (range)
Gender
Male/female
Years on AED
Mean (range)
Osteopenia/
osteoporosis
TPM 33.4 (23–67) 3/6 4.6 (2–6) 1/1
LTG 43 (19–73) 11/32 7.8 (2–19) 14/2
CBZ 50.6 (38–69) 5/7 16.8 (3–21) 5/0
VPA 43.9 (18–77) 7/8 10.5 (2–24) 5/1
OXC 37.3 (22–54) 7/5 4.5 (2 -11) 6/2
LEV 41.9 (19–69) 5/12 4.4 (2–6) 9/3
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decreased BMD was signiﬁcantly higher in patients treated with
LEV or with OXC as compared to the remaining patients (p < 0.05)
(Supplementary Fig. 1) No signiﬁcant difference was found
concerning age and gender between the group of patients treated
with LEV or OXC and the rest of the patients (Table 2).
In our patients on polytherapy, we did not ﬁnd signiﬁcant
difference between the six studied AEDs concerning the incidence
of decreased BMD.
4. Discussion
There is increasing evidence that chronic treatment with AEDs
is associated with changes in bone metabolism, increasing the risk
of fractures in patients with epilepsy. AEDs are used not only in
patients with epilepsy but also in increasing number of patients
with other conditions (headache, neuropathic pain).12,13
In order to compare the effect of different AEDs on BMD, in this
cross-sectional study we analysed data from 168 adult outpatients,
treated with 6 different AEDs.
Concerning the effect of LEV on BMD there are only few and
conﬂicting data reported in the literature.6,7 Our results suggestthat LEV is more often associated with decreased BMD compared to
the other AEDs, although the duration of therapy was signiﬁcantly
shorter (mean: 4.4 years) in the group of patients treated with LEV.
Two previous studies demonstrated decreased BMD in children
treated with OXC.8,9 Our data support that this also is the case in
adult patients.
Age and gender have not inﬂuenced our data signiﬁcantly (se
results we have described this there), thus the observed differences
in the incidence of decreased BMD cannot be attributed to these
factors. However, the sample size in the six groups of AEDs was not
sufﬁcient to analyse other co-founders, and further, multicentre
studies are needed to fully elucidate this.
Based upon our results we suggest that BMD measurement
should be considered in adult patients using also some newer
AEDs, especially LEV and OXC on long-term and not only in the case
of enzyme inducing drugs as suggested previously.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.seizure.2012.04.002.
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